Spondyloarthritis & psoriatic arthritis
Potential difficult-to-treat psoriatic arthritis real-world prevalence and contributing factors
Authors' conclusion
This study underscores the impact of comorbidities on PsA disease activity
Study context
- Population
- Patients with psoriatic arthritis (PsA) at two tertiary centres (116 [67.8%] women; mean age 48.16 ±11.23 years)
- Participants
- 171 patients
- Exposure
- Potential difficult-to-treat PsA (D2TPsA) vs non-D2TPsA
- Outcome
- Frequency of potential D2TPsA and contributing factors
Methodological detailstwo tertiary centres, multivariate analysis
- Two tertiary centres
- Multivariate analysis
Main finding
As reported in the abstract
Prevalence of potential D2TPsA
D2TPsA
19.3%
33 events
Observational data: associations, not effects.
Further findings
Factors associated with D2TPsA
- D2TPsA had longer disease duration, higher disease burden (median tender and swollen joints, patient and physician global evaluation, morning stiffness, ESR, CRP, DAPSA), HLA-B27 positivity and higher prevalence of peripheral involvement
- Secukinumab use and mean GC dosage significantly higher in D2TPsA
- Fibromyalgia (FM), diabetes mellitus (DM) and median number of comorbidities significantly higher in D2TPsA
- In multivariate analysis, FM, DM and HLA-B27 positivity independently associated with D2TPsA
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Potential difficult-to-treat psoriatic arthritis real-world prevalence and contributing factors. Clin Exp Rheumatol. Published 7 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →